Disclosures for "Genetic modifiers have an additive effect on ALS prognosis: a population-based study")
-
Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen.
-
Cristina Moglia has nothing to disclose.
-
Antonio Canosa has nothing to disclose.
-
Dr. Manera has nothing to disclose.
-
Mr. Grassano has nothing to disclose.
-
Dr. Vasta has nothing to disclose.
-
Francesca Palumbo has nothing to disclose.
-
Maura Brunetti has nothing to disclose.
-
Fabiola De Marchi has nothing to disclose.
-
Ruth Chia has nothing to disclose.
-
Dr. Mora has nothing to disclose.
-
Barbara Iazzolino has nothing to disclose.
-
Laura Peotta has nothing to disclose.
-
The institution of Dr. Traynor has received research support from ALS Association. The institution of Dr. Traynor has received research support from Merck. The institution of Dr. Traynor has received research support from Myasthenia Gravis Foundation. The institution of Dr. Traynor has received research support from Cerevel Therapeutics. Dr. Traynor has received intellectual property interests from a discovery or technology relating to health care.
-
Lucia Corrado has nothing to disclose.
-
Sandra D'Alfonso has nothing to disclose.
-
Letizia Mazzini has nothing to disclose.
-
Dr. Calvo has nothing to disclose.